Imagion Biosystems Market Herald Interview

We recently announced plans to conduct our first in-human study for MagSense in Australia later this year. In this Market Herald interview, watch IBX CEO Bob…


Investor Webcast Presentation

Imagion Biosystems has released an investor webcast presentation announcement to the market. View the webcast presentation.


Imagion announces plan to undertake first clinical study in Australia

Imagion announces plan to undertake first clinical study in Australia Live Webcast Scheduled Imagion Biosystems Limited (ASX: IBX), a company dedicated to…


Market Herald Interview

In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI…


Imagion Nanoparticle Manufacturing Update

Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense™ HER2 nanoparticle formulation under Good…


Imagion Biosystems Establishes Collaboration with Siemens Healthineers

Imagion Biosystems Limited announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to…


Imagion Biosystems Nanoparticles Used in Viral Therapy Research

Imagion Biosystems Limited is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of the…


Imagion Biosystems May 2020 Investor Newsletter

Imagion Biosystems Limited is pleased to provide investors with its May 2020 Investor Newsletter. The newsletter details recent key company developments and…


Imagion Appoints New Non-Executive Director

Imagion Biosystems Limited today announced the appointment of Ms Dianne Angus to the Board of Directors. Ms Angus joined the Board as a Non-Executive Director…


Annual Report to Shareholders

Imagion Biosystems has released its Annual Report to Shareholders for the year ended 31 December 2019. Read the Annual Report.